Live Breaking News & Updates on Excluding transplantation

Live from ASH 2023 | Oral Report Featuring Encouraging Data of Olverembatinib Combined with Reduced-Intensity Chemotherapy in Patients with Ph+ ALL Presented at the ASH Annual Meeting

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

Australia , Hong-kong , Philadelphia , Pennsylvania , United-states , San-diego , California , Suzhou , Jiangsu , China , Beijing , Rockville

Live From ASH 2023 | Oral Report Featuring Encouraging Data Of Olverembatinib Combined With Reduced-Intensity Chemotherapy In Patients With Ph+ ALL Pr...

Live From ASH 2023 | Oral Report Featuring Encouraging Data Of Olverembatinib Combined With Reduced-Intensity Chemotherapy In Patients With Ph+ ALL Pr...
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Rockville , Pennsylvania , United-states , Suzhou , Jiangsu , China , San-diego , California , Australia , Hong-kong , Philadelphia , Beijing

Treadwell Therapeutics Announces a Presentation at the 2023 ASH Annual Meeting and Advisory Board Meeting

Treadwell Therapeutics Announces a Presentation at the 2023 ASH Annual Meeting and Advisory Board Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-states , Texas , Toronto , Ontario , Canada , American , Roger-sidhu , Gautam-borthakur , Department-of-leukemia , American-society-of-hematology , Advisory-board-co , Division-of-cancer-medicine

Live from ASH 2023 | Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax in Patients with AML, Demonstrating Favorable Efficacy and Safety

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

United-states , China , Zhejiang , San-diego , California , Beijing , Rockville , Hong-kong , Suzhou , Jiangsu , Australia , American

Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Warsaw , L67- , Poland , United-states , San-diego , California , American , Hendrik-nogai , Corporatenatalia-baranowska-ryvu , John-fraunces-lifesci , Menarini-group , American-society-of-hematology

Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meeting

Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Texas , United-states , Helsinki , Eteläuomen-läi , Finland , San-diego-convention-center , California , San-diego , Boston , Massachusetts , Jukka , Lapland

MEI Pharma (MEIP) Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

MEI Pharma (MEIP) Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Davidm-urso , Matthews-davids , American-society-of-hematology , Nasdaq , Division-of-lymphoma , Dana-farber-cancer-institute , Clinical-research , Mei-pharma-inc , Harvard-medical-school

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

– Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity –

– Initial Results from Correlative Studies Demonstrate On-target...

United-states , American , Matthews-davids , Davidm-urso , American-society-of-hematology , Harvard-medical-school , Nasdaq , Pharma-inc , Clinical-research , Linkedin , Dana-farber-cancer-institute

Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL

Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Philadelphia , Pennsylvania , United-states , American , Kristen-odwyer , Anjalis-advani , Wilmot-cancer-institute , Cancer-research-network , American-society-of-hematology , University-of-rochester , Cleveland-clinic-cancer-institute , American-society

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Davida-walsey , Davidm-urso , Matthews-davids , American-society-of-hematology , Dana-farber-cancer-institute , Nasdaq , Harvard-medical-school , Pharma-inc , Division-of-lymphoma